GINS2 and neoplasm: Targeting GINS2 via shRNA knockdown combined with T cells and neutrophils showed anti-tumor activity, but the addition of anti-PD-L1 blockade yielded the most profound tumor suppression, accompanied by reduced Ki67 expression.